Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Abingworth is a life science investment firm founded in 1987. It is based in London, New York, and San Francisco. The organization focuses on helping young biopharma companies develop new treatments by providing capital, experience, and strategic guidance.
Abingworth invests in private and public companies across three strategic areas: seed and early stage, development stage, and clinical co-development. The firm typically invests in biotherapeutics, small molecules, nucleic acid therapeutics, vaccines, gene therapies, cell therapies, specialty pharmaceuticals, and platform technologies. Its investment size ranges from $15 million to $30 million for seed and early-stage companies, and a minimum of $30 million for development-stage investments, with a holding period of 2 to 10 years.
Abingworth has invested in over 100 life science companies, achieving 36 product approvals since 2012, 75 IPOs, and 52 mergers and acquisitions. Notable portfolio companies include Median Technologies, which received FDA clearance for an AI-based lung cancer screening device, and Jasper Therapeutics, which appointed a new CEO to lead its clinical growth.
To approach Abingworth, founders should submit their pitch through the firm's website at abingworth.com. The firm is particularly interested in companies developing biotherapeutics and innovative healthcare solutions.
Abingworth has achieved significant milestones in the life sciences sector, including 36 product approvals since 2012, 75 IPOs, and 52 mergers and acquisitions. Notable portfolio companies include Median Technologies and Jasper Therapeutics, showcasing the firm's active role in supporting innovative biopharma ventures.
Abingworth invests in pre-seed, seed, and growth equity stages.
Founders can pitch Abingworth through their website at abingworth.com.
Abingworth focuses on biotech and healthcare sectors, particularly biotherapeutics and innovative treatments.
Abingworth typically invests between $15 million and $30 million for seed and early-stage companies.
Abingworth invests globally, with a presence in North America and Europe.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.